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CCN2 plays a critical role in the development of mesenchymal tissues such as cartilage and bone, and
the binding of CCN2 to various cytokines and receptors regulates their signaling. By screening a pro-
tein array, we found that CCN2 could bind to ﬁbroblast growth factor receptors (FGFRs) 2 and 3, with
a higher afﬁnity toward FGFR2. We ascertained that FGFR2 bound to CCN2 and that the binding of
FGFR2 to FGF2 and FGF4 was enhanced by CCN2. CCN2 and FGF2 had a collaborative effect on the
phosphorylation of ERK and the differentiation of osteoblastic cells. The present results indicate
the biological signiﬁcance of the binding of CCN2 to FGFR2 in bone metabolism.
Structured summary of protein interactions:
FGFR2 binds to CCN2 by protein array (View interaction)
FGFR1OP binds to CCN2 by protein array (View interaction)
FGFR3 binds to CCN2 by protein array (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction CCN2 as a probe and found ﬁbroblast growth factor (FGF) receptor 2CCN2 is a member of the CCN family of proteins [1,2], and
CCN2-null mice show remarkable abnormalities in skeletal devel-
opment, as represented by bent costal cartilage and long bones
with impaired endochondral ossiﬁcation [3]. Also, in vitro studies
have shown that CCN2 is a stimulator of both the proliferation
and differentiation of chondrocytes, osteoblasts, vascular endothe-
lial cells, and mesenchymal stem cells [1,2]. These ﬁndings indicate
that CCN2 plays a critical role in the metabolism of cartilage and in
bone formation.
Nevertheless, the molecular behavior determining the effect of
CCN2 has not been totally elucidated. CCN2 is known as a binding
partner of many types of cytokines and extracellular matrix pro-
teins, such as bone morphogenetic protein (BMP) 2, ﬁbronectin,
and aggrecan [4–6]. Also, CCN2 was reported to be a modulator of
signaling by BMP2, BMP4, and TGF-b [4,7]. Therefore, we assumed
that proteins binding to CCN2 deﬁne the various effects of CCN2
in certain circumstances. Searching for new factors binding to
CCN2, we performed a protein-array experiment with recombinantchemical Societies. Published by E
Biochemistry and Molecular
edicine, Dentistry and Phar-
yama 700-8525, Japan. Fax:
. Takigawa).(FGFR2) to be among the candidates as partners of CCN2.
FGFR2 is a member of the FGF receptor family and is expressed
in condensed mesenchyme and later in sites of endochondral and
intramembranous ossiﬁcation [8]. In vitro assays show that FGFR2
regulates certain steps of skeletal development [9–11]. In humans,
mutations of FGFR2 cause endochondral diseases such as Apert and
Crouzon syndromes [12–14]. FGFR2-deﬁcient mice die at 10–11
days of gestation because of failure in the formation of their pla-
centa and limb buds [15]. These mice, deﬁcient in FGFR2 speciﬁ-
cally in the condensed mesenchyme, indicate that FGFR2 is
essential for the normal proliferation of osteoblasts and osteogenic
gene expression during postnatal bone development [16].
Based on this background, we subsequently conﬁrmed the binding
of CCN2 to FGFR2 and assessed its effects on FGFR2 signaling in
osteoblastic cell lineMC3T3-E1. Finally, we found that CCN2 enhanced
the signaling effected by FGF2-induced activation of extracellular reg-
ulated kinase (ERK), which action resulted in the collaborative
enhancement of the differentiation of the osteoblastic cells.2. Materials and methods
2.1. Screening of CCN2-binding proteins
Proteins binding to CCN2 were screened with a ProtoArray
Human Protein Microarray ver. 4 (Invitrogen, Carlsbad, CA, USA).
Experiments were professionally performed by Filgen Incorporatedlsevier B.V. All rights reserved.
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man CCN2 (BioVendor Laboratory Medicine, Brno, Czech Republic)
as a probe.
2.2. Solid-phase binding assay
For the examination of the direct interaction between CCN2 and
FGFR-Fc, a solid-phase binding assay was carried out, as described
previously [5,6]. Brieﬂy, wells of ELISA plates previously coated
with 1 lg/ml of rCCN2 (BioVendor Laboratory Medicine) or bovine
serum albumin (BSA) were blocked with blocking buffer. Diluted
recombinant human FGFR2a (IIIc)/Fc (FGFR2-Fc) or recombinant
human FGFR3a (IIIc)/Fc (FGFR3-Fc; R&D Systems, Minneapolis,
MN) was then added to the wells, and incubation was conducted
for 2 h at 37 C. Thereafter, the wells were washed and incubated
with horseradish peroxidase (HRP)-conjugated anti-human Fc
antibody (Sigma Aldrich, St Louis, MO); and the bound HRP was
then monitored by using 3,3,5,5-tetramethylbenzidine (TMB) per-
oxidase substrate (Sigma–Aldrich). The effect of CCN2 on the bind-
ing of FGFR2-Fc to FGF2 or FGF4 was assayed on ELISA plates
coated with 1 lg/ml of FGF2 or FGF4 (R&D Systems). FGFR2-Fc
was incubated with CCN2 for 30 min before being added to the
wells, and detection of signals was performed as described above.
2.3. SPR (surface plasmon resonance) measurements
For the calculation of dissociation constant (Kd) values, SPR
measurements were performed, as described previously [4,6].
Brieﬂy, FGFR2-Fc was diluted to concentrations of 1.6, 8, 40, 200,
and 1000 nM with HBS-EP (GE Healthcare UK, Ltd, Little Chalfout,
UK, Little Chalfout, UK); and each was reacted with rCCN2
immobilized on CM5 sensor chips (GE Healthcare) according to
the standard amine coupling procedure recommended by the
manufacturer. Binding and dissociation of these molecules were
monitored with a Biacore X (GE Healthcare) and the data were ﬁt-
ted using the BIAevaluation software version 4.1 (GE Healthcare)
with the single cycle kinetics support package (GE Healthcare).
The sensorgrams were corrected by subtracting the signal of the
reference cell and were forwarded for Kd computation.
2.4. Cell culture
Cells of the mouse osteoblastic cell line MC3T3-E1 were
cultured in a humidiﬁed incubator (5% CO2 in air) at 37 C and
maintained in 10% FCS/DMEM supplemented with 50 lg/ml strep-
tomycin and 100 units/ml penicillin.
2.5. Immunoprecipitation and western blotting
The cell lysate mixed with oligohistidine-tagged rCCN2 was
incubated for 2 h at 4 C and reacted with Protein G Sepharose 4
Fast Flow beads (GE Healthcare) having adsorbed anti-FGFR2 (San-
ta Cruz Biotechnology, Santa Cruz, CA) or control goat IgG for 1 h at
4 C. The precipitated protein was assayed by western blotting
analysis using rabbit anti-6-His Antibody Afﬁnity Puriﬁed (Bethyl
Laboratories, Inc., Montgomery, TX, USA).
2.6. Evaluation of ERK protein phosphorylation
Cells lysates were collected in RIPA buffer after stimulation of
the cells with FGF2, rCCN2 or FGFR2-Fc. Western blotting was car-
ried out with Anti-ACTIVE MAPK pAb, Rabbit pTEpY (Promega
Corporation, Madison, Wl) or p44/42 MAPK antibody (Cell Signal-
ing Technology, Danvers, MA). The density of each band was quan-
tiﬁed by Multi Gauge Ver3.0 (FUJIFILM, Japan).2.7. Quantitative real-time PCR analysis
Total RNA was isolated by using an RNeasy Mini Kit (Qiagen,
Hilden, Germany) and was reverse-transcribed to cDNA by using
a Takara RNA PCR kit (AMV), Version 3.0 (Takara Shuzo, Tokyo,
Japan). Ampliﬁcation reactions were performed with a SYBR
Green Real-time PCR Master Mix (Toyobo; Tokyo, Japan) by using
StepOne™ Software v2.1 (Applied Biosystems, Foster City, CA,
USA). The nucleotide sequences of the primers used were as
follow: 50-GCCAAAAGGGTCATCATCTC-30 (forward) and reverse
50-GTCT TCTGGGTGGCAGTGAT-30 (reverse) for Gapdh; 50-CTCACA-
GATGCCAAGCCCA-30 (forward) and reverse 50-CCAAGGTAGCGCCG-
GAG TCT-30 (reverse) for Osteocalcin, as reported earlier [17,23].
2.8. Statistical analysis
Statistical analyses were performed by using Student’s t-test, if
necessary. ⁄p < 0.05, and ⁄⁄p < 0.01, as compared with the values for
control wells.
3. Results
3.1. FGFR2 and 3 as candidate CCN2-binding proteins
First, we used a protein array to screen for proteins binding to
CCN2. Fig. 1 shows the CCN2 binding proﬁle of the FGF-associated
molecules included in the protein array. Among the top 3 candi-
dates, we focused on FGFR2 and 3, because their mutants are
known to result in genetic disorders of bone formation, in which
CCN2 plays a critical role. Thus, these 2 molecules were forwarded
for subsequent investigation.
3.2. Speciﬁc binding of CCN2 to FGFR2 and FGFR3
To conﬁrm the binding of CCN2 to FGFR2 and 3, we initially em-
ployed a solid-phase binding assay, which results are displayed in
Fig. 2(A) and (B). Though FGFR2-Fc and FGFR3-Fc increasingly bound
to CCN2 depending upon the doses, the bound FGFR2-Fc is more
than twice as much as FGFR3-Fc in each dose. Both FGFR2 and 3
bound to CCN2 hardly bound to wells coated with BSA, which
protein was used as a negative control for CCN2 protein. Similarly,
human IgG used as a negative control for FGFR fused to human IgG
Fc domain did not bind to CCN2 at all (data not shown). These results
mean that the binding of FGFR2 and 3 to CCN2 was speciﬁc and the
binding of FGFR2 appeared to be stronger than that of FGFR3. On the
basis of these results, we decided to further investigate the mode
and functional signiﬁcance of the binding of FGFR2 to CCN2.
First we analyzed the afﬁnity of CCN2 to FGFR2 by performing
SPR analysis (Fig. 2(C)). SPR assay indicated the Kd value for the
binding of CCN2 to FGFR2 to be 7.71 nM. According to previous
studies, the Kd values for FGF1, 2 and 4, which are known as li-
gands of FGFR2, were reported to be 0.791 nM, 0.490 nM, and
0.412 nM, respectively [17]. These data taken together indicate
that the binding afﬁnity of CCN2 for FGFR2 was not equivalent,
but at least comparable, to that of known FGFR2 ligands.
Next, the binding of FGFR2 in vivo to CCN2 was ascertained by
co-immunoprecipitation of FGFR2 on MC3T3-E1 cells with rCCN2
(Fig. 2(D)). Much more CCN2 protein was detected in the immuno-
precipitant with anti-FGFR2 Ab than with control Ab. These data
represent CCN2 bound to FGFR2 expressed on MC3T3-E1.
3.3. Effect of CCN2–FGFR2 interaction on the binding of FGFs to FGFR2
The major function of FGFR2 is to transmit the signals from its
authentic ligands. Therefore, we veriﬁed whether or not this bind-
ing of CCN2 to FGFR2 could inﬂuence the binding of FGFR2 to its
Fig. 1. Protein array analysis suggesting strong interaction of CCN2 with FGFR2 and FGFR3. The ProtoArray Human protein microarray was probed with His-tagged CCN2,
and FGF and associated factors were extracted from the results and ranked by signal intensities in descending order.
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normal bone formation (Fig. 3(A) and (B)). As a result, we found that
the binding of FGFR2 to FGF4 was less strong than that to FGF2.
However, in the case of both FGF2 and FGF4, the presence of
CCN2 dose-dependently enhanced the binding of FGFR2 to these
FGFs.
3.4. Functional signiﬁcance of the CCN2-FGFR2 interaction
Finally, we examined the effect of CCN2 on the intracellular sig-
naling after FGFR2 in an osteoblastic cell line, MC3T3-E1. Fig. 4
shows that CCN2 enhanced the activation of ERK triggered by
FGF2. The activation of ERK induced by FGF4 (10 ng/ml) was
weaker than that by FGF2, but was also increased by CCN2 (data
not shown). The activation of ERK was suppressed by the addition
of a fusion protein of the extracellular domain of FGFR2 and immu-
noglobulin FC region, indicating that FGF2 and CCN2 induced this
phosphorylation of ERK essentially via signaling from FGFR2.
According to previous reports, FGFR2 signaling increases the
expression of osteoblastic markers in MC3T3-E1 cells [8,10,11];
however, the effect of FGF2 on the differentiation of osteoblasts
still remains controversial [18–21]. To gain new insight into this is-
sue, we evaluated the combinational effect of FGF2 and CCN2 on
the expression of osteocalcin, a typical osteoblastic marker. CCN2
was added with or without FGF2 to subconﬂuent cultures of
MC3T3-E1 cells. After 7 days, the expression of osteocalcin was as-
sayed as described in Section 2. As shown in Fig. 5, CCN2 and FGF2
cooperatively enhanced the expression of the osteocalcin gene. Of
note, the enhancement was suppressed in presence of FGFR2-Fcprotein. These results suggest the requirement of FGF signaling
for the promotion of osteoblastic differentiation by CCN2.4. Discussion
This report demonstrates for the ﬁrst time the novel interac-
tion between human CCN2 and FGFR2. We conﬁrmed that the
binding of FGFR2 to CCN2 was comparably efﬁcient as that to
its known ligands by performing the solid-phase binding assay
and SPR analysis. Interestingly, the presence of CCN2 enhanced
the binding of FGFR2 to its authentic ligands, FGF2 and FGF4,
in a CCN2 dose-dependent manner. Moreover, intracellular FGF
signaling was enhanced in the presence of CCN2. A previous re-
port showed that CCN2 could also bind to FGF2 [22]. These ﬁnd-
ings together indicate that CCN2 may enhance the cross-linking
of FGFR2 and these FGFs via forming tri-molecular complexes.
Furthermore, according to another report, CCN2 binds to heparin
[23], which is known as a cofactor for the binding of FGFs to their
receptors. Therefore, the fully functional FGFR2 complex that
accepts FGF signals at best efﬁciency on the cell surface may
be composed of CCN2, proteoglycan, and FGFR2. Indeed, we
assessed the possibility that CCN2 acted as a co-receptor like
heparin in vitro, but CCN2 did not increase or decrease the dimer-
ization of FGFR2 in the presence or absence of heparin (data not
shown).
According to previous studies, the signaling via FGFR2 enhances
osteoblastic differentiation of pre-osteoblast cell lines or bone
marrow stromal cells [9,11]. However, although FGF2 is a potent
Fig. 2. Binding of CCN2 to FGFR2 conﬁrmed by results of solid-phase binding assay and SPR analysis. Solid-phase binding assay showed that FGFR2-Fc (A) and FGFR3-Fc (B)
bound to CCN2 in a dose dependent manner. FGFR-Fc protein was incubated on ELISA plates pre-coated with CCN2 or BSA (a negative control for CCN2 protein). Bound FGFR2-
Fc or FGFR3-Fc was detected with anti-Fc antibody-HRP and HRP substrate (TMB). The amount of FGFR-Fc binding to wells was represented as the absorbance (450 nm) in
each well corrected by subtracting that of blank wells. Data are representative of 2 independent experiments. The data are mean values ±S.D. of 3 wells. (C) The indicated
dilutions of FGFR2-Fc were injected onto a CCN2 -immobilized Biacore sensor chip. The Kd value was calculated by using BIAevaluation software, as described in Section 2. (D)
Recombinant CCN2 bound to FGFR2 expressed on MC3T3-E1 cells. MC3T3-E1 cells suspended in with 10% FCS/aMEM were plated at the density of 10  105/dish per 6-cm
dish and cultured in the medium for a week. The media was changed at day 3. The cell lysate (740 lg protein) mixed with oligohistidine-tagged rCCN2 (2.5 lg) was incubated
for 2 h and precipitated with 50 ll protein G Sepharose gel having adsorbed anti-FGFR2 Ab or control goat IgG. The proteins in the gel and rCCN2 (2 lg/lane) were subjected
to western blotting analysis using anti-His Ab. Positions of molecular weight standards are indicated at the right. Arrowhead indicates the CCN2 protein.
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perfectly clear. In this study we demonstrated that CCN2 and FGF2
cooperatively enhanced the osteoblastic differentiation of MC3T3-
E1. However CCN2 or FGF2 alone did not necessarily enhance the
osteoblastic differentiation under the experimental conditions em-
ployed, though both of them were used at optimal doses describedin the reports using other cell lines [20,24]. We also tried a few
doses up to 2–5 times higher than the optimal ones, but no stron-
ger effects were observed (data not shown). Debiais et al. described
that the positive or negative effects of FGF2 on the mineralization
and expression of osteocalcin depend on the stage of cell differen-
tiation [20]. At the early stage, FGF2 decreases this phenotype;
Fig. 3. CCN2 enhances the binding of FGFR2-Fc with FGF2. FGFR-Fc protein and CCN2 were incubated on ELISA plates pre-coated with FGF2 (A) or FGF4 (B). The bound FGFR-
Fc was detected with anti-Fc antibody-HRP and TMB substrate. Optical absorbance in each well was measured and corrected by subtracting that of blank wells. Data are
representative of 2 independent experiments and are the mean values ±S.D. of 3 wells. ⁄p < 0.05 and ⁄⁄p < 0.01, as compared with the value for the control wells incubated
with FGFR2-Fc alone.
Fig. 4. CCN2 promotes the activation of ERK by FGF2 in osteoblastic MC3T3-E1
cells. MC3T3-E1 cells in a-modiﬁcation of MEM containing 10% FCS were plated at
the density of 4  105/well in 6-well plates. After a 24-h incubation, the cells were
cultured in 0.5% FCS/aMEM for another 24 h and then stimulated with FGF2 (2 ng/
ml) with or without CCN2 (100 ng/ml) and FGFR-Fc. The lysates were collected at
30 min after stimulation for western blotting analysis with the indicated antibodies.
The blots are representative of 2 independent experiments. The lower panel shows
the ratio between the optical densities of phospho-ERK and total ERK.
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expression of FGFR2 is up-regulated after the middle stage. Our
present data indicates that CCN2 supported the signaling of FGF2via FGFR2, which increased the expression of osteocalcin. Never-
theless, in this experiment, FGF2 alone did not clearly inﬂuence
the expression of this osteoblastic marker. This result appears con-
tradictory to the study cited above, but 2 possibilities that may ac-
count for this discrepancy can be presented. Firstly, MC3T3-E1 cells
under our conditions might not have expressed enough FGFR2 to
fully respond to FGF2. Secondly, in the experiments performed in
the previous study, CCN2 could be already present at a sufﬁcient
amount to support the signaling via FGFR2. In fact, a recent report
showed that CCN2 gene expression in osteoblasts reaches its peak
after 14 days following the induction of differentiation in vitro
[25,26].
Another study using a different experimental system also
showed that CCN2 displays a cooperative effect with FGF2 [26],
but the machinery at work was not elucidated. Based on the results
obtained in this study, we propose the possible machinery yielding
the effect of CCN2 via FGFR2 on osteoblastic differentiation. Our
present study clearly showed that CCN2 enhanced the ERK-
mediated signal emitted by the FGFR2/FGF2 complex via direct
molecular interaction, which enhanced the differentiation of
osteoblastic cells, and such effects were nulliﬁed by a FGFR2
signaling inhibitor. These ﬁndings collectively indicate the
FGFR2-dependency of one aspect of CCN2 function, conﬁrming
the molecular action of CCN2 as a signal conductor for harmonized
bone development and regeneration. In addition, it remains to be
clariﬁed whether this FGFR2/CCN2 interaction is critically involved
in similar effects of CCN2 on cells other than osteoblasts.
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